12601 Twinbrook Parkway, Rockville, MD 20852 USA
Phone Calls:301-816-81298 a.m. to 5 p.m. EST Mon. - Fri.
ATTENTION !
USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the
statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.
ATORVASTATIN RELATED COMPOUND C
Catalog Number:1044549
Revision Date:
February 5, 2009
SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION
Common Name:
Atorvastatin Calcium Related Compound C
Manufacturer:U. S. Pharmacopeia
Responsible Party:Reference Standards Technical Services
Mailing Address:12601 Twinbrook Parkway, Rockville, MD 20852 USAPhone:301-816-8129
Hours:8 a.m. to 5 p.m. EST Mon. - Fri.
Product Use:USP Reference Standards and Authentic Substances are used for chemical tests and assays in analytical,
clinical, pharmaceutical, and research laboratories.
SECTION 2 - HAZARD INFORMATIONEMERGENCY OVERVIEW : Reproductive Hazard
Information on the chemical, physical, and toxicological properties of this material is not readily available. Individuals working with this chemical should consider it to be potentially hazardous, even if its actual hazards may be uncharacterized or unknown. For reference, available information on a related item, atorvastatin, is provided.
Adverse Effects:Adverse effects of statins such as atorvastatin calcium, a related compound, may include muscle pain, weakness,
stiffness, or tenderness; numbness or tingling in arms or legs; fever; unusual tiredness or weakness; headache; dizziness; constipation; diarrhea; gas; heartburn or indigestion; stomach pain; nausea; skin rash; decreased sexual ability; trouble sleeping; and upper respiratory infection. It is not known if this compound causes the same effects. Possible allergic reaction to material if inhaled, ingested, or in contact with skin.Overdose Effects:n/f
Acute:Possible eye, skin, gastrointestinal, and/or respiratory tract irritation.Chronic:Possible hypersensitization and liver damage.
Medical Conditions Aggravated by Exposure:Hypersensitivity to material; active liver disease or history of; active alcoholism;
unexplained, persistent elevations in transaminase values; severe electrolyte,
endocrine, or metabolic disorders; severe infection; myopathy; uncontrolled seizures; organ transplant with immunosuppressant therapy; kidney impairment; and amyotrophic lateral sclerosis (ALS).Cross Sensitivity:Persons sensitive to HMG-CoA reductase inhibitors (e.g., fluvastatin, lovastatin, pravastatin) may be sensitive to this
material also. Copyright © 2009 The United States Pharmacopeial Convention, Inc. All Rights Reserved.
n/f = not found
Page 1 of 5
ATORVASTATIN RELATED COMPOUND C
Catalog Number:1044549Target Organs:Liver
For additional information on toxicity, see Section 11.
Revision Date:
February 5, 2009
SECTION 3 - COMPOSITION/INFORMATION ON INGREDIENTS
Common Name:Atorvastatin Calcium Related Compound CFormula:C33H33F2N2O5 . 1/2 Ca
Synonym:Atorvastatin calcium difluoro impurity
Chemical Name:(3R,5R)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
calcium saltCAS:693793-53-2RTECS Number:n/fChemical Family:n/fTherapeutic Category:n/fComposition:Pure material
SECTION 4 - FIRST AID MEASURESInhalation:May cause irritation. Remove to fresh air.
Eye:May cause irritation. Flush with copious quantities of water.Skin:May cause irritation. Flush with copious quantities of water.Ingestion:May cause irritation. Flush out mouth with water.
General First Aid Procedures:Remove from exposure. Remove contaminated clothing. Persons developing serious hypersensitivity
(anaphylactic) reactions must receive immediate medical attention. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen. Obtain medical attention.
Note to Physicians
Overdose Treatment:Treatment of statin overdose should be symptomatic and supportive and may include the following:
1. Administer activated charcoal as an aqueous slurry.
2. For rhabdomyolysis, administer 0.9% saline to maintain urine output of 2 - 3 milliliters/kg/hour. Monitor fluid balance, serum electrolytes, CPK, liver enzymes, and renal function. Administer diuretics if needed to maintain urine output. Urinary alkalinization is not recommended.
3. Hemodialysis is not expected to enhance clearance. [Poisindex 2009]
SECTION 5 - FIREFIGHTING MEASURES
Extinguisher Media:Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.
Fire and Explosion Hazards:This material is assumed to be combustible. As with all dry powders, it is advisable to ground mechanical
equipment in contact with dry material to dissipate the potential buildup of static electricity. Firefighting Procedures:As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing
equipment and protective clothing.
SECTION 6 - ACCIDENTAL RELEASE MEASURES
Spill Response:Wear approved respiratory protection, chemically compatible gloves, and protective clothing. Wipe up spillage or
collect spillage using a high-efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.
SECTION 7 - HANDLING AND STORAGE
Copyright © 2009 The United States Pharmacopeial Convention, Inc. All Rights Reserved.
Page 2 of 5
n/f = not found
ATORVASTATIN RELATED COMPOUND C
Catalog Number:1044549
Revision Date:
February 5, 2009
Handling:As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors
associated with the material. Wash thoroughly after handling. Storage:
Store in tight, light-resistant container as defined in the USP-NF.This material should be handled and stored per label instructions to ensure product integrity. Store in a dry place. Store in a refrigerator. This material is hygroscopic.
SECTION 8 - EXPOSURE CONTROL / PERSONAL PROTECTION
Engineering Controls:Engineering controls such as exhaust ventilation are recommended.
Respiratory Protection:Use a NIOSH-approved respirator, if it is determined to be necessary by an industrial hygiene survey
involving air monitoring. In the event that a respirator is not required, an approved dust mask should be used.Gloves:
Chemically compatible
Eye Protection:Safety glasses or gogglesProtective Clothing:Protect exposed skin.Exposure Limits:n/f
SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Properties as indicated on the MSDS are general and not necessarily specific to the USP Reference Standard Lot provided.Appearance and Odor:white granular powderOdor Threshold:n/fpH:n/f
Melting Range:n/fBoiling Point:n/fFlash Point:n/f
Autoignition Temperature:n/fEvaporation Rate:n/fUpper Flammability Limit:n/fLower Flammability Limit:n/fVapor Pressure:n/fVapor Density:n/fSpecific Gravity:n/fSolubility in Water:n/fFat Solubility:
n/f
Other Solubility:n/f
Partition Coefficient: n-octanol/water:n/fPercent Volatile:n/fReactivity in Water:n/fExplosive Properties:n/fOxidizing Properties:n/fFormula:
C33H33F2N2O5 . 1/2 Ca
Molecular Weight:595.67
Copyright © 2009 The United States Pharmacopeial Convention, Inc. All Rights Reserved. n/f = not foundPage 3 of 5
ATORVASTATIN RELATED COMPOUND C
Catalog Number:1044549
Revision Date:
February 5, 2009
SECTION 10 - STABILITY AND REACTIVITY
Conditions to Avoid:Light, heat, and moisture.Incompatibilities:
n/f
Decomposition Products:When heated to decomposition, material emits toxic fumes of NOx and HF. Emits toxic fumes under fire
conditions.Stable?Yes
Hazardous Polymerization?No
SECTION 11 - TOXICOLOGICAL PROPERTIES
Oral Rat:n/fOral Mouse:
n/f
Other Toxicity Data:n/f Irritancy Data:Corrosivity:
n/fn/f
Sensitization Data:n/fListed as a Carcinogen by:Other Carcinogenicity Data:n/fMutagenicity Data:
n/f
NTP:No
IARC:
No
OSHA:No
Reproductive and Developmental Effects:Therapeutic use of statins such as atorvastatin calcium, a related compound, during
pregnancy is not recommended because they decrease cholesterol and may decrease cholesterol-derived substances essential for fetal development. Results of animal studies indicate that many statins are associated with adverse fetal outcomes at maternally toxic doses. It is not known if this compound causes the same effects.
SECTION 12 - ECOLOGICAL INFORMATION
Ecological Information:n/f
SECTION 13 - DISPOSAL CONSIDERATIONS
Disposal:
Dispose of waste in accordance with all applicable Federal, State, and local laws.
SECTION 14 -TRANSPORT INFORMATION
Shipping Name:Class:
n/f
UN Number:n/fPacking Group:
n/fn/f
Additional Transport Information:n/f
SECTION 15 - REGULATORY INFORMATION
U.S. Regulatory Information:
n/f
International Regulatory Information:n/f
SECTION 16 - OTHER INFORMATION
Copyright © 2009 The United States Pharmacopeial Convention, Inc. All Rights Reserved. n/f = not foundPage 4 of 5
ATORVASTATIN RELATED COMPOUND C
Catalog Number:1044549Revision:
05-Feb-09
15-Oct-08
Revision Date:
February 5, 2009
Previous Revision Date:
Copyright © 2009 The United States Pharmacopeial Convention, Inc. All Rights Reserved. n/f = not foundPage 5 of 5
因篇幅问题不能全部显示，请点此查看更多更全内容